TAP and Gallus Co-host Free Webinar
News Oct 01, 2014
TAP Biosystems has announced that it will be co-presenting a new bioprocess webinar with major US contract manufacturing organization (CMO) Gallus BioPharmaceuticals, on Thursday November 6th 2014 at 4pm GMT /5pm CEST / 8am PST / 11am EST.
The live event will detail how Gallus is using the ambr15™ automated microbioreactor system as a tool for implementing DoE (Design of Experiments) to accelerate biosimilar process development.
Bioprocessing experts, Dr. Matt Zustiak, Principal Scientist at Gallus BioPharmaceuticals and Dr. Joanne Swihart, ambr15 Product Specialist at TAP Biosystems, will present data on how the ambr15 micro bioreactor system mimics large-scale cell culture to enable rapid process development for biosimilars. To access the free webinar, scientists can register at: http://view6.workcast.net/register?pak=7140783969312062.
During the 60 minute webinar, Dr. Swihart will introduce the ambr15 system and its potential in shortening process scale-up timelines, with industry data demonstrating the consistency and scalability of ambr15 when compared to benchtop and larger scale bioreactors.
Dr. Matt Zustiak will then outline Gallus’ use of the ambr15 system in their new Process Development facility for DoE as part of their QbD (Quality by Design) strategy of biosimilar development. In his presentation, Dr. Zustiak will discuss the impact of media and feeds on critical quality attributes, as well as how to identify key process parameters.
Dr. Joanne Swihart, TAP Biosystems’ ambr15 Product Specialist explained: "Using a QbD approach, CMOs can deliver biosimilars with higher yields and titres. However, implementing DoE in a QbD framework can involve running and analyzing results from hundreds of process parameter combinations. For most companies this is just not feasible, and explains why high throughput process development modelling tools are critical to success.”
Dr. Swihart continued: “I’m excited to host this new webinar with Matt Zustiak in which we’ll present data showing how ambr15 offers an intelligent method for rapidly assessing a large number of parallel media and feed parameters in a DoE context. This will demonstrate how ambr15 is helping develop robust, high performance cell culture processes, ensuring Gallus’ top pharma and biotech clients can rapidly deliver cost-effective biosimilars to market.”
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE